                </a></li></ul></div><p><strong>Figure 1.  <span>CV mortality in males and females according to the <em>GYS1</em> XbaI (A) and <em>APOE</em> –219/ε2/ε3/ε4 (B) genotypes.</span></strong></p><a id="article1.body1.sec3.sec3.fig1.caption1.p1" name="article1.body1.sec3.sec3.fig1.caption1.p1"></a><p>Kaplan Meier survival curves illustrating a higher risk for CV mortality (HR 1.8 [1.2–2.6], p = 0.0016, p<sub>c</sub> = 0.0096) in male carriers of the <em>GYS1</em> XbaI CT/TT-genotypes and in female carriers of the <em>APOE</em> –219TT/ε4 genotype combination (HR 2.3 [1.6–3.2], p&lt;0.0001, p<sub>c</sub>&lt;0.0001).</p>
<span>THISISTHEEND
